{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T05:33:25Z","timestamp":1736919205502,"version":"3.33.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.2515\/therapie:2003014","type":"journal-article","created":{"date-parts":[[2007,3,16]],"date-time":"2007-03-16T10:38:23Z","timestamp":1174041503000},"page":"97-105","source":"Crossref","is-referenced-by-count":0,"title":["Nouveaux hypolip\u00e9miants : prospectives"],"prefix":"10.1016","volume":"58","author":[{"given":"Michel","family":"Farnier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2003014_bb2600","first-page":"897","article-title":"Synthetic optically pure statins","volume":"3","author":"Farnier","year":"2000","journal-title":"Drugs"},{"key":"10.2515\/therapie:2003014_bb2605","doi-asserted-by":"crossref","first-page":"28B","DOI":"10.1016\/S0002-9149(01)01454-0","article-title":"Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor","volume":"87","author":"McTaggart","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.2515\/therapie:2003014_bb2610","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/13543784.11.1.125","article-title":"Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia","volume":"11","author":"Davidson","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.2515\/therapie:2003014_bb2615","doi-asserted-by":"crossref","first-page":"33B","DOI":"10.1016\/S0002-9149(01)01455-2","article-title":"Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin","volume":"87","author":"Olsson","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.2515\/therapie:2003014_bb2620","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/174182670100800608","article-title":"Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study","volume":"8","author":"Paoletti","year":"2001","journal-title":"J Cardiovasc Risk"},{"key":"10.2515\/therapie:2003014_bb2625","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0002-9149(01)02226-3","article-title":"Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia","volume":"89","author":"Davidson","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.2515\/therapie:2003014_bb2630","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0002-9149(99)00656-6","article-title":"Effects of NK-104, a new hydroxy-methylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia","volume":"85","author":"Kajinami","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.2515\/therapie:2003014_bb2635","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0021-9150(01)00712-2","article-title":"A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia","volume":"162","author":"Saito","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2003014_bb2640","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.2515\/therapie:2003014_bb2645","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(01)00638-6","article-title":"Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia","volume":"110","author":"Knapp","year":"2001","journal-title":"Am J Med"},{"key":"10.2515\/therapie:2003014_bb2650","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(01)00437-3","article-title":"Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively","volume":"158","author":"Hunninghake","year":"2001","journal-title":"Atherosclerosis"},{"issue":"Suppl. E","key":"10.2515\/therapie:2003014_bb2655","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1016\/S1520-765X(01)90106-3","article-title":"Ezetimibe: a selective inhibitor of cholesterol absorption","volume":"3","author":"Catapano","year":"2001","journal-title":"Eur Heart J"},{"key":"10.2515\/therapie:2003014_bb2660","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.bjp.0704260","article-title":"Ezetimibe selectively inhibitis intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function","volume":"134","author":"van Heek","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.2515\/therapie:2003014_bb2665","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/sj.bjp.0703235","article-title":"Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH 58235, and its glucuronide, SCH 60663","volume":"129","author":"van Heek","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.2515\/therapie:2003014_bb2670","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-2999(01)00825-1","article-title":"The cholesterol absorption inhibitor; ezetimibe, decreases diet-induced hypercholesterolemia in monkeys","volume":"415","author":"van Heek","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.2515\/therapie:2003014_bb2675","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1053\/meta.2001.26737","article-title":"The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in dogs","volume":"50","author":"Davis","year":"2001","journal-title":"Metabolism"},{"key":"10.2515\/therapie:2003014_bb2680","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/hq1201.100260","article-title":"Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoE knockout mice","volume":"21","author":"Davis","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.2515\/therapie:2003014_bb2685","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0149-2918(01)80102-8","article-title":"Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies","volume":"23","author":"Bays","year":"2001","journal-title":"Clin Ther"},{"issue":"Suppl. 2","key":"10.2515\/therapie:2003014_bb2690","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1567-5688(01)80027-1","article-title":"Ezetimibe reduces low-density lipoprotein cholesterol: results of a phase III, randomised, double-blind, placebo-controlled trial [abstract]","volume":"2","author":"Knopp","year":"2001","journal-title":"Atherosclerosis"},{"issue":"Suppl. II","key":"10.2515\/therapie:2003014_bb2695","first-page":"176","article-title":"Ezetimibe, a selective cholesterol absorption inhibitor, improves plasma lipids in hypercholesterolemic patients [abstract]","volume":"104","author":"Dujovne","year":"2001","journal-title":"Circulation"},{"issue":"Suppl. E","key":"10.2515\/therapie:2003014_bb2700","first-page":"E11-6","article-title":"Results of phase I\/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor","volume":"3","author":"Stein","year":"2001","journal-title":"Eur Heart J"},{"issue":"Suppl. A","key":"10.2515\/therapie:2003014_bb2705","doi-asserted-by":"crossref","first-page":"226A","DOI":"10.1016\/S0735-1097(02)81010-5","article-title":"Ezetimibe coadministered with simvastatin in 668 patients with primary hypercholesterolemia [abstract]","volume":"39","author":"Davidson","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. A","key":"10.2515\/therapie:2003014_bb2710","doi-asserted-by":"crossref","first-page":"227A","DOI":"10.1016\/S0735-1097(02)81011-7","article-title":"Ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia [abstract]","volume":"39","author":"Ballantyne","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.2515\/therapie:2003014_bb2715","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministrated with atorvastatin and simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagn\u00e9","year":"2002","journal-title":"Circulation"},{"issue":"Suppl. 2","key":"10.2515\/therapie:2003014_bb2720","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1567-5688(01)80026-X","article-title":"Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe [abstract]","author":"Kosoglou","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2003014_bb2725","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00041433-200106000-00008","article-title":"Roles of acyl-coenzyme A: cholesterol acyltransferase-1 and -2","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Lipidol"},{"key":"10.2515\/therapie:2003014_bb2730","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11883-002-0064-9","article-title":"Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis?","volume":"4","author":"Heinonen","year":"2002","journal-title":"Curr Atheroscler Rep"},{"key":"10.2515\/therapie:2003014_bb2735","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0022-2275(20)33494-5","article-title":"Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs","volume":"40","author":"Burnett","year":"1999","journal-title":"J Lipid Res"},{"key":"10.2515\/therapie:2003014_bb2740","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0021-9150(97)00279-7","article-title":"The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters","volume":"137","author":"Nicolosi","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2003014_bb2745","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1161\/01.ATV.20.1.70","article-title":"The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits","volume":"20","author":"Bocan","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.2515\/therapie:2003014_bb2750","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1161\/01.CIR.103.13.1778","article-title":"Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice","volume":"103","author":"Delsing","year":"2001","journal-title":"Circulation"},{"key":"10.2515\/therapie:2003014_bb2755","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0021-9150(01)00441-5","article-title":"Effect of F-1394, an acyl-CoA: cholesterol acyltransferase inhibitor, on atherosclerosis induced by high cholesterol diet in rabbits","volume":"158","author":"Aragane","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2003014_bb2760","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0021-9150(98)00046-X","article-title":"HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit","volume":"139","author":"Bocan","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2003014_bb2765","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0021-9150(00)00713-9","article-title":"The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression","volume":"157","author":"Bocan","year":"2001","journal-title":"Atheroclerosis"},{"key":"10.2515\/therapie:2003014_bb2770","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0021-9150(00)00559-1","article-title":"F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet","volume":"155","author":"Junquero","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2003014_bb2775","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0021-9150(00)00615-8","article-title":"Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia","volume":"157","author":"Insull","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2003014_bb2780","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0022-2275(20)36957-1","article-title":"Plasma cholesteryl ester transfer protein","volume":"34","author":"Tall","year":"1993","journal-title":"J Lipid Res"},{"key":"10.2515\/therapie:2003014_bb2785","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00041433-200012000-00010","article-title":"Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?","volume":"11","author":"von Eckardstein","year":"2000","journal-title":"Curr Opin Lipidol"},{"key":"10.2515\/therapie:2003014_bb2790","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0021-9150(85)90064-4","article-title":"Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinemia","volume":"58","author":"Koizumi","year":"1985","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2003014_bb2795","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/01.ATV.20.5.1323","article-title":"Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study","volume":"20","author":"Ordovas","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.2515\/therapie:2003014_bb2800","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/01.ATV.0000024566.57589.2E","article-title":"Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency. Veterans Affairs HDL cholesterol Intervention Trial","volume":"22","author":"Brousseau","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.2515\/therapie:2003014_bb2805","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199801083380203","article-title":"The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group","volume":"338","author":"Kuivenhoven","year":"1998","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie:2003014_bb2810","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":"A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits","volume":"406","author":"Okamoto","year":"2000","journal-title":"Nature"},{"key":"10.2515\/therapie:2003014_bb2815","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0021-9150(01)00705-5","article-title":"Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage","volume":"162","author":"Kobayashi","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2003014_bb2820","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1161\/01.CIR.0000015857.31889.7B","article-title":"Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study","volume":"105","author":"de Grooth","year":"2002","journal-title":"Circulation"},{"key":"10.2515\/therapie:2003014_bb2825","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.282.5389.751","article-title":"An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits","volume":"282","author":"Wetterau","year":"1998","journal-title":"Science"},{"key":"10.2515\/therapie:2003014_bb2830","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1021\/jm000494a","article-title":"A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors","volume":"44","author":"Robl","year":"2001","journal-title":"J Med Chem"},{"key":"10.2515\/therapie:2003014_bb2835","first-page":"16","article-title":"Bay 13-9952 (implitapide), an inhibitor of the microsomal triglyceride transfer protein (MTP), inhibits atherosclerosis and prolongs lifetime in apo-E knockout mice [abstract 194]","volume":"21","author":"Zaiss","year":"2000","journal-title":"Eur Heart J"},{"key":"10.2515\/therapie:2003014_bb2840","first-page":"II-601","article-title":"Inhibition of post prandial fat absorption with the MTP inhibitor Bay 13\u20139952","volume":"102","author":"Stein","year":"2000","journal-title":"Circulation"},{"year":"2001","series-title":"Efficacy and safety of implitapide, a microsomal triglyceride transfer protein inhibitor in patients with primary hypercholesterolemia","author":"Farnier","key":"10.2515\/therapie:2003014_bb2845"},{"key":"10.2515\/therapie:2003014_bb2850","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00041433-200106000-00002","article-title":"Peroxisome proliferator-activated receptors: from transcriptional control to clincial practice","volume":"12","author":"Torra","year":"2001","journal-title":"Curr Opin Lipidol"},{"key":"10.2515\/therapie:2003014_bb2855","doi-asserted-by":"crossref","first-page":"24N-9N","DOI":"10.1016\/S0002-9149(01)02149-X","article-title":"Peroxisome proliferator-activated receptor-\u03b1 activation and high-density lipoprotein metabolism","volume":"88","author":"Fruchart","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.2515\/therapie:2003014_bb2860","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.ATV.0000015598.86369.04","article-title":"Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis","volume":"22","author":"Barbier","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.2515\/therapie:2003014_bb2865","doi-asserted-by":"crossref","first-page":"16638","DOI":"10.1074\/jbc.275.22.16638","article-title":"Peroxisome proliferator-activated receptor \u03b1 activators improve insulin sensitivity and reduce adiposity","volume":"275","author":"Guerre-Millo","year":"2000","journal-title":"J Biol Chem"},{"key":"10.2515\/therapie:2003014_bb2870","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1002\/j.1460-2075.1996.tb00918.x","article-title":"PPAR\u03b1 and PPAR\u03b3 activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene","volume":"15","author":"Schoojans","year":"1996","journal-title":"EMBO J"},{"key":"10.2515\/therapie:2003014_bb2875","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1006\/bbrc.1999.0951","article-title":"Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor \u03b1","volume":"260","author":"Murakami","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.2515\/therapie:2003014_bb2880","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0026-0495(00)80019-0","article-title":"Tissue-specific action of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats","volume":"49","author":"Ide","year":"2000","journal-title":"Metabolism"},{"key":"10.2515\/therapie:2003014_bb2885","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S0026-0495(99)90158-0","article-title":"Amelioration by KRP-297, a new thiazolidinedione, of impaired glucose uptake in skeletal muscle from obese insulin-resistant animals","volume":"48","author":"Murakami","year":"1999","journal-title":"Metabolism"},{"key":"10.2515\/therapie:2003014_bb2890","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0969-2126(01)00634-7","article-title":"Structure of the PPAR\u03b1 and -\u03b3 ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family","volume":"9","author":"Cronet","year":"2001","journal-title":"Structure"},{"key":"10.2515\/therapie:2003014_bb2895","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11883-002-0065-8","article-title":"Gut-acting drugs for lowering cholesterol","volume":"4","author":"Black","year":"2002","journal-title":"Curr Atheroscler Rep"},{"key":"10.2515\/therapie:2003014_bb2900","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0022-3565(24)39237-7","article-title":"New molecular targets for cholesterol-lowering therapy","volume":"293","author":"Izzat","year":"2000","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716300713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716300713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T23:43:23Z","timestamp":1736898203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716300713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["S0040595716300713"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2003014","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}